JP2015505477A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505477A5 JP2015505477A5 JP2014555736A JP2014555736A JP2015505477A5 JP 2015505477 A5 JP2015505477 A5 JP 2015505477A5 JP 2014555736 A JP2014555736 A JP 2014555736A JP 2014555736 A JP2014555736 A JP 2014555736A JP 2015505477 A5 JP2015505477 A5 JP 2015505477A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- gene
- light chain
- chain constant
- rodent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 103
- 241000283984 Rodentia Species 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 18
- 150000007523 nucleic acids Chemical group 0.000 claims description 16
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 15
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 12
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 9
- 230000004048 modification Effects 0.000 claims description 9
- 238000012986 modification Methods 0.000 claims description 9
- 108091008324 binding proteins Proteins 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 238000011144 upstream manufacturing Methods 0.000 claims description 8
- 108700005091 Immunoglobulin Genes Proteins 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 2
- 102000025171 antigen binding proteins Human genes 0.000 claims description 2
- 108091000831 antigen binding proteins Proteins 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 210000001161 mammalian embryo Anatomy 0.000 claims description 2
- 102000023732 binding proteins Human genes 0.000 claims 4
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 1
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 1
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 1
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 1
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261593463P | 2012-02-01 | 2012-02-01 | |
| US61/593,463 | 2012-02-01 | ||
| US201261677538P | 2012-07-31 | 2012-07-31 | |
| US61/677,538 | 2012-07-31 | ||
| PCT/US2013/024295 WO2013116609A1 (en) | 2012-02-01 | 2013-02-01 | Humanized rodents that express heavy chains containing vl domains |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018022012A Division JP6698718B2 (ja) | 2012-02-01 | 2018-02-09 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015505477A JP2015505477A (ja) | 2015-02-23 |
| JP2015505477A5 true JP2015505477A5 (enExample) | 2016-03-03 |
Family
ID=47714588
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555736A Withdrawn JP2015505477A (ja) | 2012-02-01 | 2013-02-01 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2018022012A Active JP6698718B2 (ja) | 2012-02-01 | 2018-02-09 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2019130027A Active JP6942757B2 (ja) | 2012-02-01 | 2019-07-12 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2021099420A Active JP7187615B2 (ja) | 2012-02-01 | 2021-06-15 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2022191963A Active JP7525579B2 (ja) | 2012-02-01 | 2022-11-30 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2023173593A Pending JP2023168590A (ja) | 2012-02-01 | 2023-10-05 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018022012A Active JP6698718B2 (ja) | 2012-02-01 | 2018-02-09 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2019130027A Active JP6942757B2 (ja) | 2012-02-01 | 2019-07-12 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2021099420A Active JP7187615B2 (ja) | 2012-02-01 | 2021-06-15 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2022191963A Active JP7525579B2 (ja) | 2012-02-01 | 2022-11-30 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2023173593A Pending JP2023168590A (ja) | 2012-02-01 | 2023-10-05 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20130212719A1 (enExample) |
| EP (3) | EP2809150B1 (enExample) |
| JP (6) | JP2015505477A (enExample) |
| KR (2) | KR20190006029A (enExample) |
| CN (2) | CN104202971B (enExample) |
| AU (3) | AU2013204758B2 (enExample) |
| BR (1) | BR112014018843B1 (enExample) |
| CA (1) | CA2863175A1 (enExample) |
| CY (2) | CY1122419T1 (enExample) |
| DK (2) | DK3597038T3 (enExample) |
| ES (2) | ES2870703T3 (enExample) |
| HR (2) | HRP20192218T1 (enExample) |
| HU (2) | HUE055610T2 (enExample) |
| IL (3) | IL233827A0 (enExample) |
| LT (2) | LT2809150T (enExample) |
| ME (1) | ME03611B (enExample) |
| MX (2) | MX2020003491A (enExample) |
| NZ (5) | NZ810648A (enExample) |
| PL (2) | PL2809150T3 (enExample) |
| PT (2) | PT2809150T (enExample) |
| RS (2) | RS62023B1 (enExample) |
| RU (2) | RU2664185C2 (enExample) |
| SG (3) | SG10201913428QA (enExample) |
| SI (2) | SI2809150T1 (enExample) |
| SM (2) | SMT201900685T1 (enExample) |
| WO (1) | WO2013116609A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2436044T3 (es) * | 2008-05-23 | 2013-12-26 | Ablexis, Llc | Procedimiento de generación de anticuerpos de dominio VL individual en animales transgénicos |
| CN102638971B (zh) | 2009-07-08 | 2015-10-07 | 科马布有限公司 | 动物模型及治疗分子 |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| KR102306967B1 (ko) | 2010-08-02 | 2021-10-01 | 리제너론 파아마슈티컬스, 인크. | Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스 |
| PT3865581T (pt) | 2011-08-05 | 2024-10-04 | Regeneron Pharma | Murganhos da cadeia leve universal humanizada |
| AU2012311286B2 (en) | 2011-09-19 | 2018-07-26 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| GB201122047D0 (en) * | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| PT3527070T (pt) | 2011-12-20 | 2025-12-19 | Regeneron Pharma | Murganhos de cadeia leve humanizada |
| NZ810648A (en) * | 2012-02-01 | 2025-11-28 | Regeneron Pharma | Humanized rodents that express heavy chains containing vl domains |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| EP3912464A1 (en) | 2012-06-12 | 2021-11-24 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
| MY185881A (en) | 2013-02-20 | 2021-06-14 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| CA2925723A1 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
| CN106255410B (zh) | 2014-03-21 | 2020-01-10 | 瑞泽恩制药公司 | 产生单结构域结合蛋白的非人动物 |
| CN106164092A (zh) | 2014-03-21 | 2016-11-23 | 瑞泽恩制药公司 | 表现不同结合特征的vl抗原结合蛋白 |
| US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| WO2016161446A1 (en) * | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| CN118185874A (zh) * | 2016-04-04 | 2024-06-14 | 苏黎世联邦理工学院 | 一种重组哺乳动物b细胞 |
| US20170332610A1 (en) | 2016-05-20 | 2017-11-23 | Regeneron Pharmaceuticals, Inc. | Methods for breaking immunological tolerance using multiple guide rnas |
| US11089767B2 (en) * | 2017-03-30 | 2021-08-17 | Utah State University | Transgenic silkworms expressing spider silk |
| TW202438676A (zh) * | 2017-12-05 | 2024-10-01 | 美商再生元醫藥公司 | 具有經改造免疫球蛋白λ輕鏈的非人類動物及其用途 |
| SG11202008799PA (en) * | 2018-03-24 | 2020-10-29 | Regeneron Pharma | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
| IL318469A (en) * | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| KR20230066386A (ko) | 2020-09-11 | 2023-05-15 | 리제너론 파마슈티칼스 인코포레이티드 | 항원 특이적 항체의 확인 및 제조 |
| AU2021400584A1 (en) | 2020-12-16 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| CN114645042A (zh) * | 2020-12-18 | 2022-06-21 | 中国食品药品检定研究院 | 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法 |
| CN114196626A (zh) * | 2022-02-16 | 2022-03-18 | 北京国卫生物科技有限公司 | 脐带间充质干细胞及其分离培养扩增方法 |
| CN118339300A (zh) * | 2024-01-02 | 2024-07-12 | 江苏集萃药康生物科技股份有限公司 | 产生人源化抗体的动物模型及其构建方法 |
| CN121065267A (zh) * | 2024-06-04 | 2025-12-05 | 赛业（苏州）生物科技有限公司 | 用于制备四元固定轻链的基因修饰的啮齿动物及其制备方法 |
| WO2026030428A2 (en) | 2024-08-01 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Prostate-specific antigen peptides and uses thereof |
| US20260123608A1 (en) | 2024-08-06 | 2026-05-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof |
| WO2026096736A1 (en) | 2024-10-31 | 2026-05-07 | Regeneron Pharmaceuticals, Inc. | Rodents expressing humanized polymeric immunoglobulin receptor |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
| EP1311530A4 (en) * | 2000-08-03 | 2004-10-06 | Wim-Van Schooten | PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CN101016543A (zh) * | 2000-11-17 | 2007-08-15 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法 |
| US7473557B2 (en) | 2001-06-06 | 2009-01-06 | Regeneron Pharmaceuticals, Inc. | Method for targeting transcriptionally active loci |
| EP1458852B1 (en) * | 2001-12-21 | 2011-03-09 | ThromboGenics N.V. | Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells |
| WO2003081993A2 (en) * | 2002-03-22 | 2003-10-09 | Origen Therapeutics | Transgenic aves producing human polyclonal antibodies |
| CN103205436B (zh) * | 2003-07-15 | 2016-05-25 | 人类多克隆治疗公司 | 人源化免疫球蛋白基因座 |
| WO2006044962A1 (en) | 2004-10-19 | 2006-04-27 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
| CN101084317A (zh) * | 2004-10-22 | 2007-12-05 | 人类多克隆治疗公司 | 对内源免疫球蛋白表达的抑制 |
| JP5514539B2 (ja) * | 2006-03-31 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物 |
| ES2378407T3 (es) * | 2006-09-01 | 2012-04-12 | Therapeutic Human Polyclonals, Inc. | Aumento de la expresión de inmunoglobulina humana o humanizada en animales transgénicos no humanos |
| CN101970491A (zh) * | 2007-08-30 | 2011-02-09 | 沃尔特及伊莱萨霍尔医学研究院 | 树突状细胞标记物及其用途 |
| EP3415529B1 (en) * | 2007-09-26 | 2020-11-04 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
| US7659842B2 (en) | 2007-10-24 | 2010-02-09 | Infineon Technologies Ag | Quantization error reduction in PWM full-MASH converters |
| ES2436044T3 (es) * | 2008-05-23 | 2013-12-26 | Ablexis, Llc | Procedimiento de generación de anticuerpos de dominio VL individual en animales transgénicos |
| RU2731084C2 (ru) * | 2008-06-27 | 2020-08-28 | Мерюс Н.В. | Продуцирующие антитела млекопитающие, не являющиеся человеком |
| WO2010022738A1 (en) * | 2008-08-29 | 2010-03-04 | Symphogen A/S | Method for cloning avian-derived antibodies |
| US9085795B2 (en) * | 2009-02-04 | 2015-07-21 | Molecular Innovations, Inc. | Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies |
| CN102638971B (zh) * | 2009-07-08 | 2015-10-07 | 科马布有限公司 | 动物模型及治疗分子 |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| CN103228130B (zh) * | 2010-06-17 | 2016-03-16 | 科马布有限公司 | 动物模型及治疗分子 |
| KR102306967B1 (ko) * | 2010-08-02 | 2021-10-01 | 리제너론 파아마슈티컬스, 인크. | Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스 |
| LT2738259T (lt) * | 2011-02-25 | 2020-03-10 | Regeneron Pharmaceuticals, Inc. | Adam6 pelės |
| PT3865581T (pt) * | 2011-08-05 | 2024-10-04 | Regeneron Pharma | Murganhos da cadeia leve universal humanizada |
| PT3527070T (pt) * | 2011-12-20 | 2025-12-19 | Regeneron Pharma | Murganhos de cadeia leve humanizada |
| NZ810648A (en) * | 2012-02-01 | 2025-11-28 | Regeneron Pharma | Humanized rodents that express heavy chains containing vl domains |
| EP3912464A1 (en) * | 2012-06-12 | 2021-11-24 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
| PT4082334T (pt) * | 2016-11-04 | 2025-05-21 | Regeneron Pharma | Animais não humanos possuindo um lócus da cadeia leve lambda de immunoglobulina geneticamente modificada |
-
2013
- 2013-02-01 NZ NZ810648A patent/NZ810648A/en unknown
- 2013-02-01 NZ NZ793447A patent/NZ793447A/en unknown
- 2013-02-01 SG SG10201913428QA patent/SG10201913428QA/en unknown
- 2013-02-01 PT PT137043295T patent/PT2809150T/pt unknown
- 2013-02-01 RU RU2014133653A patent/RU2664185C2/ru active
- 2013-02-01 SI SI201331592T patent/SI2809150T1/sl unknown
- 2013-02-01 NZ NZ627977A patent/NZ627977A/en active IP Right Revival
- 2013-02-01 EP EP13704329.5A patent/EP2809150B1/en active Active
- 2013-02-01 ME MEP-2019-348A patent/ME03611B/me unknown
- 2013-02-01 PT PT191910819T patent/PT3597038T/pt unknown
- 2013-02-01 MX MX2020003491A patent/MX2020003491A/es unknown
- 2013-02-01 HR HRP20192218TT patent/HRP20192218T1/hr unknown
- 2013-02-01 KR KR1020187037872A patent/KR20190006029A/ko not_active Ceased
- 2013-02-01 ES ES19191081T patent/ES2870703T3/es active Active
- 2013-02-01 LT LT13704329T patent/LT2809150T/lt unknown
- 2013-02-01 DK DK19191081.9T patent/DK3597038T3/da active
- 2013-02-01 CN CN201380017544.2A patent/CN104202971B/zh active Active
- 2013-02-01 NZ NZ734504A patent/NZ734504A/en unknown
- 2013-02-01 HU HUE19191081A patent/HUE055610T2/hu unknown
- 2013-02-01 RU RU2018122695A patent/RU2770016C2/ru active
- 2013-02-01 SM SM20190685T patent/SMT201900685T1/it unknown
- 2013-02-01 EP EP19191081.9A patent/EP3597038B1/en active Active
- 2013-02-01 SG SG11201404477YA patent/SG11201404477YA/en unknown
- 2013-02-01 DK DK13704329T patent/DK2809150T3/da active
- 2013-02-01 NZ NZ719228A patent/NZ719228A/en unknown
- 2013-02-01 PL PL13704329T patent/PL2809150T3/pl unknown
- 2013-02-01 HU HUE13704329A patent/HUE046744T2/hu unknown
- 2013-02-01 US US13/756,889 patent/US20130212719A1/en not_active Abandoned
- 2013-02-01 PL PL19191081T patent/PL3597038T3/pl unknown
- 2013-02-01 KR KR1020147024417A patent/KR20140123983A/ko not_active Ceased
- 2013-02-01 SM SM20210401T patent/SMT202100401T1/it unknown
- 2013-02-01 SG SG10201606256TA patent/SG10201606256TA/en unknown
- 2013-02-01 MX MX2019002517A patent/MX373286B/es active IP Right Grant
- 2013-02-01 JP JP2014555736A patent/JP2015505477A/ja not_active Withdrawn
- 2013-02-01 RS RS20210791A patent/RS62023B1/sr unknown
- 2013-02-01 BR BR112014018843-2A patent/BR112014018843B1/pt active IP Right Grant
- 2013-02-01 SI SI201331882T patent/SI3597038T1/sl unknown
- 2013-02-01 EP EP21167681.2A patent/EP3912465A1/en active Pending
- 2013-02-01 AU AU2013204758A patent/AU2013204758B2/en active Active
- 2013-02-01 CN CN201610371631.3A patent/CN106117364B/zh active Active
- 2013-02-01 RS RS20191615A patent/RS59699B1/sr unknown
- 2013-02-01 ES ES13704329T patent/ES2753774T3/es active Active
- 2013-02-01 LT LTEP19191081.9T patent/LT3597038T/lt unknown
- 2013-02-01 WO PCT/US2013/024295 patent/WO2013116609A1/en not_active Ceased
- 2013-02-01 CA CA2863175A patent/CA2863175A1/en active Pending
-
2014
- 2014-07-27 IL IL233827A patent/IL233827A0/en active IP Right Grant
-
2015
- 2015-10-23 AU AU2015246154A patent/AU2015246154B2/en active Active
-
2016
- 2016-10-14 US US15/294,488 patent/US20170094955A1/en not_active Abandoned
-
2017
- 2017-10-27 AU AU2017251848A patent/AU2017251848B2/en active Active
-
2018
- 2018-02-09 JP JP2018022012A patent/JP6698718B2/ja active Active
- 2018-08-21 IL IL261280A patent/IL261280B/en active IP Right Grant
-
2019
- 2019-07-12 JP JP2019130027A patent/JP6942757B2/ja active Active
- 2019-08-13 IL IL268675A patent/IL268675B/en active IP Right Grant
- 2019-12-10 CY CY20191101302T patent/CY1122419T1/el unknown
-
2021
- 2021-04-07 US US17/224,524 patent/US20210368751A1/en not_active Abandoned
- 2021-06-15 JP JP2021099420A patent/JP7187615B2/ja active Active
- 2021-06-23 HR HRP20210987TT patent/HRP20210987T1/hr unknown
- 2021-07-20 CY CY20211100659T patent/CY1124361T1/el unknown
-
2022
- 2022-11-30 JP JP2022191963A patent/JP7525579B2/ja active Active
-
2023
- 2023-10-05 JP JP2023173593A patent/JP2023168590A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015502177A5 (enExample) | ||
| JP2015519076A5 (enExample) | ||
| RU2014127339A (ru) | Мыши с гуманизированной легкой цепью | |
| RU2014133653A (ru) | Гуманизированные грызуны, которые экспрессируют тяжелые цепи, содержащие домены vl | |
| JP2018138047A5 (enExample) | ||
| JP2014524243A5 (enExample) | ||
| JP2020501516A5 (enExample) | ||
| HRP20201403T1 (hr) | Neljudske životinje koje imaju genetski modificiran lokus imunoglobulinskog lambda lakog lanca | |
| JP2021137030A5 (enExample) | ||
| JP2014110814A5 (enExample) | ||
| RU2014153673A (ru) | Гуманизированные не относящиеся к человеку животные с ограниченными локусами тяжелой цепи иммуноглобулина | |
| JP2019047806A5 (enExample) | ||
| HRP20170322T1 (hr) | Miševi koji stvaraju vl vezne proteine | |
| JP2015509380A5 (enExample) | ||
| JP2013532974A5 (enExample) | ||
| JP2015525071A5 (enExample) | ||
| JP2011182801A5 (enExample) | ||
| JP2013535213A5 (enExample) | ||
| JP2015510767A5 (enExample) | ||
| JP2020530760A5 (enExample) | ||
| RU2019121863A (ru) | Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения | |
| HRP20230490T1 (hr) | Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina | |
| HRP20160497T1 (hr) | Mišji hibridni laki lanac | |
| HRP20171357T1 (hr) | Ograničeni teški lanac imunoglobulina u miševa | |
| JP2015510769A5 (enExample) |